Show simple item record

dc.contributor.authorStenmarck, Mille Sofie
dc.contributor.authorEngen, Caroline Benedicte Nitter
dc.contributor.authorStrand, Roger
dc.date.accessioned2022-01-31T13:34:09Z
dc.date.available2022-01-31T13:34:09Z
dc.date.created2021-10-05T14:43:52Z
dc.date.issued2021
dc.identifier.issn1472-6939
dc.identifier.urihttps://hdl.handle.net/11250/2976038
dc.description.abstractBackground As the range of therapeutic options in the field of oncology increases, so too does the strain on health care budgets. The imbalance between what is medically possible and financially feasible is frequently rendered as an issue of tragic choices, giving rise to public controversies around health care rationing. Main body We analyse the Norwegian media discourse on expensive cancer drugs and identify four underlying premises: (1) Cancer drugs are de facto expensive, and one does not and should not question why. (2) Cancer drugs have an indubitable efficacy. (3) Any lifetime gained for a cancer patient is an absolute good, and (4) cancer patients and doctors own the truth about cancer. Applying a principle-based approach, we argue that these premises should be challenged on moral grounds. Within the Norwegian public discourse, however, the premises largely remain unchallenged due to what we find to be unjustified claims of moral superiority. We therefore explore alternative framings of the issue of expensive cancer drugs and discuss their potential to escape the predicament of tragic choices. Conclusions In a media discourse that has seemingly stagnated, awareness of the framings within it is necessary in order to challenge the current tragic choices predicament the discourse finds itself in. In order to allow for a discourse not solely concerned with the issue of tragic choices, the premises that underlie it must be subjected to critical examination. As the field of oncology advances rapidly, we depend on a discussion of its opportunities and challenges that is meaningful, and that soberly addresses the future of cancer care—both its potential and its limits.en_US
dc.language.isoengen_US
dc.publisherBMCen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleReframing cancer: challenging the discourse on cancer and cancer drugs—a Norwegian perspectiveen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright The Author(s) 2021en_US
dc.source.articlenumber126en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.1186/s12910-021-00693-5
dc.identifier.cristin1943470
dc.source.journalBMC Medical Ethicsen_US
dc.relation.projectNorges forskningsråd: 223250en_US
dc.identifier.citationBMC Medical Ethics. 2021, 22, 126.en_US
dc.source.volume22en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal